Novel AKT Pathway Inhibitor ARQ 092 Safe in Phase 1 Trial
The novel oral selective AKT pathway inhibitor ARQ 092 exhibits a manageable safety profile among patients with advanced solid tumors, according to research presented at AACR 2013.
AACR 2013
Combination Immunotherapy Approach Offers Clinical Benefit in Recurrent Ovarian Cancer
Combining dendritic cell-based autologous whole tumor antigen vaccination with adoptive lymphocyte transfer using tumor antigen-specific T cells shows promise in treating women with recurrent ovarian cancer, according to research presented at AACR 2013.
Intermittent Dosing Might Prevent Vemurafenib Resistance in Melanoma
Intermittent dosing might delay or prevent the development of vemurafenib resistance and drug-dependent tumor growth in patients with melanoma, according to research presented at AACR 2013.
African American Women Have Higher Mortality from Breast Cancer Not Explained by Subtype
African American women have worse survival and less treatable breast cancer, but higher mortality observed cannot be attributed entirely to differential diagnosis by subtype, according to research presented at AACR 2013.
Early Safety, Efficacy Demonstrated for Investigational PI3 Kinase Inhibitor GDC-0032 against Some Breast Cancers
The investigational oral PI3 kinase inhibitor GDC-0032 exhibits a favorable safety profile and early signs of promising activity against PI3 kinase alpha-mutation hormone receptor-positive breast tumors, according to research presented at the American Association for Cancer Research Annual Meeting 2013.
Novel ERK Inhibitor Shows Preclinical Promise Against BRAF, MEK-associated Drug Resistance
SCH772984 shows promise against tumor growth driven by BRAF and RAS mutations and might prove useful against tumor resistance to BRAF and MEK inhibitors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2013.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AACR 2013
Loading... 
Loading...